Docetaxel Plus Oxaliplatin with 5-Fluorouracil May Be Effective for Advanced Gastric Cancer
Docetaxel, oxaliplatin, and 5-fluorouracil (TEF) may be effective for the treatment of patients with advanced gastric cancer.
Docetaxel, oxaliplatin, and 5-fluorouracil (TEF) may be effective for the treatment of patients with advanced gastric cancer.
Patients with gastric cancer who received adjuvant chemoradiotherapy have higher survival rates compared with those who have only adjuvant.
Potential link between an individual’s consumption of dairy products and their risk of gastric cancer.
Eradicating Heliobacter pylori reduces risk for developing gastric cancer for more than 10 years.
FDA has approved ramucirumab (Cyramza; Eli Lilly) for use in combination with paclitaxel for the treatment of gastric cancer.
Adjuvant chemoradiotherapy is associated wither longer survival in patients with D2 lymphadenectomy.
Adjuvant capecitabine with oxaliplatin after gastrectomy is a viable option for patients with operable stage gastric cancer.
Postoperative treatment with somatostatin decreases the volume and duration of drainage in advanced gastric cancer.
More research is warranted to determine the effectiveness of Botox® (onabotulinumtoxinA) injections in slowing the growth of tumors.
Researchers overcame a previous barrier to studying certain features of stomach cancer cells—the necessity to have a large amount of DNA.